Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1737055 | 0.76 | AXL (0.34) | — | |
| SCHEMBL2323688 | 0.76 | DPP4 (0.35) | — | |
| SCHEMBL2208829 | 0.71 | — | — | |
| SCHEMBL3288721 | 0.68 | — | — | |
| SCHEMBL9390808 | 0.67 | DPP4 (0.33) | CSNK2A1 | |
| SCHEMBL18721950 | 0.66 | — | — | |
| SCHEMBL311677 | 0.63 | ALDH1A1 (0.34) | — | |
| SCHEMBL9437096 | 0.60 | PI4KA (0.34) | — | |
| SCHEMBL21121896 | 0.60 | DYRK1A (0.32) | CHEK1 | |
| Hydrochloric Acid SCHEMBL7218019 | 0.58 | GUSB (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035373-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12297203-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12173026-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-12-24 | — | — | US | disclosed |
| CN-119080779-A | Pyrrolopyrimidine ITK inhibitors | 阿克拉瑞斯治疗股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-112805006-B | PRMT5 inhibitors | 默沙东有限责任公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-112823005-B | Pyrrolopyrimidine ITK inhibitors | 阿克拉瑞斯治疗股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240132505-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| WO-1996040705-A1 | C-4' MODIFIED ADENOSINE KINASE INHIBITORS | GENSIA SICOR (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5506347-A | ADENOSINE KINASE INHIBITOR | GENSIA, INC. (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0684953-A1 | ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES | GENSIA, INC. (US) | 1995-12-06 | — | — | EP | disclosed |
| EP-0682519-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1994017803-A9 | ADENOSINE KINASE INHIBITORS | — | 1994-09-29 | — | — | WO | disclosed |
| WO-1994018215-A1 | ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1994017803-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1992012718-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| EP-0496617-A1 | Adenosine kinase inhibitors | GENSIA, INC. (US) | 1992-07-29 | — | — | EP | disclosed |
| US-4968686-A | DECREASED CYTOTOXICITY; CYTOMEGALO AND HERPEX SIMPLEX VIRUSES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1990-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035373-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | JAK3, JAK1, JAK2 | CSNK2A1 91/4885CHEK1 1099/4885 |
| US-20240132505-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ITK, PDXK, DMPK | CSNK2A1 480/4885CHEK1 911/4885 |
| US-12173026-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | CSNK2A1 1865/4885CHEK1 642/4885 |
| US-12297203-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | CSNK2A1 480/4885CHEK1 911/4885 |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | CSNK2A1 480/4885CHEK1 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.